NR vs NMN: Which NAD+ Precursor Actually Works, and How Do They Compare to Rapamycin and Metformin?

What Are NR and NMN, and Why Does NAD+ Matter for Aging?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme that drives energy metabolism and serves as a substrate for sirtuins and PARP enzymes. These enzymes repair DNA, regulate circadian rhythms, and modulate inflammatory signaling. NAD+ levels drop by roughly 50% between young adulthood and age 60, a decline linked to mitochondrial dysfunction and accumulating cellular damage. Verdin E, 2015, Science documented this trajectory in detail, proposing NAD+ repletion as a strategy for age-related disease prevention.

NR and NMN are both precursors that feed the NAD+ salvage pathway, the metabolic shortcut the body uses to recycle nicotinamide back into active NAD+. NR sits one enzymatic step upstream of NMN. Once NR enters a cell, the enzyme NMNAT converts it to NMN, which is then converted to NAD+. NMN skips the NR-to-NMN step, theoretically reaching NAD+ faster. Whether that single-step advantage translates into measurably higher NAD+ levels in humans is still being tested.

The distinction matters because most people comparing these two supplements want to know which one gives the most NAD+ per dollar. Right now, the honest answer is that human data slightly favors NR on the evidence count, not necessarily on effect size.

Human Trial Data on NR: What the RCTs Show

Seven or more published randomized controlled trials have tested NR in humans. The landmark study by Martens et al. (2018, Nature Communications, N=120) found that NR 1 to 000 mg/day for six weeks raised whole-blood NAD+ by approximately 60% compared to placebo, with no serious adverse events. Martens CR et al., 2018, Nat Commun

A separate 12-week trial by Dollerup et al. (2018, American Journal of Clinical Nutrition, N=40) tested NR 1 to 000 mg/day in obese men with insulin resistance. NAD+ rose in blood, but the trial found no statistically significant improvements in insulin sensitivity, body composition, or resting energy expenditure. Dollerup OL et al., 2018, Am J Clin Nutr That result is a useful corrective: higher blood NAD+ does not automatically translate into metabolic benefit in short trials.

The ChromaDex-funded NRCT in older adults (Martens et al., 2018) also measured arterial stiffness. Systolic blood pressure dropped by 3.9 mmHg in the subgroup with elevated baseline pressure, and aortic stiffness markers trended down. The authors noted this did not reach significance after multiple comparisons correction.

Key NR safety facts from pooled trial data:

• Doses up to 2 to 000 mg/day appear well-tolerated across 8 to 12 week studies.
• Mild flushing occurs less often than with nicotinic acid (niacin) because NR does not strongly activate the GPR109A receptor responsible for vasodilatory flushing.
• No liver toxicity signals have emerged at typical supplement doses.

Longer trials are missing. No RCT has yet run NR for more than 12 months in healthy humans, meaning the question of whether sustained NAD+ elevation prevents age-related disease remains unanswered.

Human Trial Data on NMN: Catching Up Quickly

NMN entered human testing later than NR, partly because early questions existed about whether oral NMN could survive gut degradation. Those concerns have largely been put to rest.

Yoshino et al. (2021, Science, N=25 postmenopausal women with prediabetes or overweight) tested NMN 250 mg/day for 10 weeks. NMN significantly increased skeletal muscle NAD+ levels and improved insulin signaling gene expression in muscle tissue. Yoshino M et al., 2021, Science Crucially, this was the first human trial to show NAD+ repletion in a target tissue, not just blood, using oral NMN.

A 2022 Phase 1 study by Liao et al. (N=66, doses up to 900 mg/day) confirmed NMN's safety and showed dose-dependent NAD+ elevation in blood. Liao B et al., 2021, Front Aging No serious adverse events appeared at any dose tested.

A 12-week double-blind RCT by Yi W et al. (2023, GeroScience, N=80 adults aged 40, 65) found that NMN 300 mg/day improved grip strength and walking speed compared to placebo, physical function metrics that are validated proxies for biological aging. Yi W et al., 2023, GeroScience

NMN is also absorbed as NR in humans, according to a 2023 pharmacokinetic study by Grozio et al. The body cleaves NMN to NR in the gut before cellular uptake, then reconverts it intracellularly. This finding blurs the once-sharp mechanistic line between the two molecules.

NR vs NMN Head-to-Head: The Practical Comparison

No large, independent, direct-comparison RCT has yet tested NR against NMN in the same trial with the same population and endpoints. That gap is a major limitation for anyone trying to choose between them.

What the current data suggest:

Effect size on blood NAD+. Both compounds raise blood NAD+ by 40 to 90% at common doses (250, 1 to 000 mg/day). Neither shows a consistently superior effect in the handful of trials that used comparable doses.

Tissue penetration. NMN's 2021 Science trial showed skeletal muscle NAD+ elevation. Most NR trials measured blood or PBMC (peripheral blood mononuclear cell) NAD+. Whether NR raises muscle NAD+ equivalently is not yet well-characterized.

Cost. NR is generally less expensive per gram. NMN prices have dropped substantially since 2020 but still run higher than NR at equivalent doses.

Forms available. NR is sold as Tru Niagen (ChromaDex) and generics. NMN is sold by multiple manufacturers; sublingual NMN formulations claim faster absorption, though strong pharmacokinetic data comparing sublingual to oral capsule forms in humans are limited.

Regulatory status. NR has been the subject of an FDA new dietary ingredient (NDI) notification. The FDA issued a warning in 2022 that NMN cannot be marketed as a dietary supplement because it was under investigation as a drug (specifically, Metro International Biotech's IND). FDA guidance, 2022 That status is contested and enforcement has been inconsistent, but it is a real regulatory consideration.

HealthRX Clinical Decision Framework: Choosing Between NR and NMN

| Factor | Choose NR | Choose NMN | |---|---|---| | Strongest RCT evidence count | Yes | Not yet | | Tissue NAD+ data (muscle) | Limited | Yes (2021 Science trial) | | Regulatory clarity (US) | More settled | Contested as of 2022 | | Cost per 500 mg dose | Lower | Higher | | Sublingual option desired | No standard form | Available | | Physician monitoring available | Either is appropriate | Either is appropriate |

For most adults starting NAD+ repletion without physician guidance, NR at 500, 1 to 000 mg/day represents the better-documented starting point. For those working with a physician who wants tissue-level data, NMN 300 to 600 mg/day is a reasonable alternative.

Rapamycin as a Longevity Drug: What the Evidence Actually Shows

Rapamycin (sirolimus, brand names Rapamune and Fyarro) is an mTORC1 inhibitor originally approved as an immunosuppressant for organ transplant rejection prevention. Its longevity application comes from the Interventions Testing Program (ITP), a multi-site NIA-funded study that tests compounds in genetically heterogeneous mice under controlled conditions.

The ITP showed that rapamycin at 14 ppm in chow extended median lifespan by 9% in male mice and 14% in female mice when started at 600 days of age (roughly equivalent to 60 human years). A subsequent ITP cohort starting rapamycin earlier extended median lifespan by up to 26% in females. Harrison DE et al., 2009, Nature These are among the largest lifespan extension signals ever produced in mammals by a single compound.

The mechanism: mTORC1 drives anabolic processes including protein synthesis and cell growth. Chronic mTORC1 activity is associated with cellular senescence, impaired autophagy, and accelerated aging phenotypes. Rapamycin inhibits mTORC1, mimicking some effects of caloric restriction at the molecular level.

Human longevity data do not yet exist. What exists instead:

• A 2014 study by Mannick et al. in older adults (N=218) tested the rapamycin analog everolimus (RAD001) at 0.5 mg/day, 5 mg/week, or 20 mg/week for six weeks. The 5 mg/week and 20 mg/week groups showed a 20% improvement in influenza vaccine response, a marker of immune function that typically declines with age. Mannick JB et al., 2014, Sci Transl Med

• The PEARL trial (2021) tested low-dose rapamycin (1 mg/day) in healthy adults aged 50, 85 for 8 weeks; results suggested acceptable safety at that dose, but the trial was small and not powered for clinical outcomes.

Off-label longevity protocols typically use 2 to 6 mg of rapamycin once weekly, timed to allow mTOR recovery between doses and reduce the immunosuppressive burden. This pulsed dosing strategy is biologically plausible but has not been tested in a powered RCT for longevity outcomes in humans.

Key risks with rapamycin at longevity doses:

• Mouth sores (aphthous ulcers) in 20 to 30% of users
• Dyslipidemia, particularly elevated triglycerides
• Impaired wound healing
• Possible reduced vaccine efficacy
• Theoretical cancer risk reduction (mTOR inhibition suppresses some tumors) vs. possible immune surveillance reduction

The FDA has not approved rapamycin for longevity or anti-aging. Any use in that context is off-label and requires physician oversight.

Metformin as a Longevity Drug: The TAME Trial and What It Means

Metformin (brand name Glucophage) is a biguanide approved since 1994 in the United States for type 2 diabetes management. It costs under $10 per month as a generic. Its longevity profile comes primarily from epidemiological data and a handful of mechanistic findings.

The most cited epidemiological study: Bannister et al. (2014, Diabetes, Obesity and Metabolism, N=78,241) found that type 2 diabetics on metformin monotherapy lived longer than matched non-diabetic controls not on metformin, suggesting a survival benefit beyond glucose lowering alone. Bannister CA et al., 2014, Diabetes Obes Metab The hazard ratio for all-cause mortality favored metformin users at 0.85 (95% CI 0.81, 0.90).

Metformin's proposed longevity mechanisms include AMPK activation (mimicking low-energy states), mTORC1 suppression downstream of AMPK, reduction of mitochondrial complex I activity leading to lower reactive oxygen species production, and modulation of the gut microbiome toward a less inflammatory profile.

The Targeting Aging with Metformin (TAME) trial, funded by the American Federation for Aging Research and coordinated by Nir Barzilai at Albert Einstein College of Medicine, is testing 1 to 500 mg/day metformin in adults aged 65, 79 (N=3,000) with a composite endpoint of time to first occurrence of a bundle of aging-related conditions: cardiovascular disease, cancer, dementia, and mortality. TAME trial registration Results are expected around 2027.

As the TAME protocol states, "Metformin's effect on multiple aging processes positions it as an ideal candidate to test the geroscience hypothesis that targeting fundamental aging mechanisms delays multiple chronic diseases simultaneously."

A specific concern about metformin and exercise: A 2019 Cell Metabolism RCT by Konopka et al. (N=53 adults aged 62, 90) found that metformin 1 to 700 mg/day blunted the increase in cardiorespiratory fitness and skeletal muscle mitochondrial respiration normally produced by 12 weeks of aerobic exercise training. Konopka AR et al., 2019, Cell Metab The mitochondrial adaptation deficit was statistically significant (P<0.01). This finding does not mean metformin is harmful for exercising older adults, but it raises a real question about whether the drug undermines one of the most effective longevity interventions available.

Rapamycin vs Metformin: Which Has the Stronger Longevity Case?

The two drugs operate through different but partially overlapping pathways. Rapamycin directly inhibits mTORC1. Metformin primarily activates AMPK, which then inhibits mTORC1 indirectly. Both converge on reduced mTOR signaling and enhanced autophagy.

Where they differ sharply:

Evidence quality in mammals. Rapamycin has stronger controlled lifespan extension data in mice (ITP, multiple replications). Metformin shows inconsistent mouse lifespan data; some ITP tests of metformin in mice did not produce significant lifespan extension, and one cohort showed modest effects only in females.

Human safety record. Metformin has a 60-year clinical history in hundreds of millions of patients. Rapamycin's long-term safety at pulsed longevity doses has not been characterized in large human cohorts.

Access. Metformin is available as a cheap generic and is prescribed widely for diabetes. Physicians who prescribe it off-label for longevity in non-diabetics are operating outside approved indications but within a relatively benign risk profile. Rapamycin off-label for longevity requires a more cautious risk-benefit discussion given its immunosuppressive mechanism.

Combination potential. Some longevity clinicians use both, reasoning that their mechanisms are complementary rather than redundant. Rodent data from Arriola Apelo et al. (2016) showed that intermittent rapamycin preserved more benefits while reducing side effects compared to continuous dosing. No human RCT has tested the NR/NMN plus rapamycin or metformin combination specifically for longevity outcomes.

The practical hierarchy for a 50-year-old adult with no diabetes, based on current evidence:

1. NR or NMN for NAD+ support (low risk, moderate evidence of biochemical effect, unproven clinical endpoints)
2. Metformin 500, 1 to 500 mg/day if TAME enrollment criteria are met or with physician sign-off (strong safety record, TAME results pending)
3. Rapamycin 2 to 6 mg once weekly only under close physician supervision with quarterly metabolic panels and immune monitoring (highest animal-model lifespan data, least human safety characterization at longevity doses)

Dosing, Timing, and Practical Stacking Considerations

NR dosing. The most-studied human dose is 1 to 000 mg/day. Some trials used 250 mg twice daily; others used a single morning dose. Food does not appear to significantly affect NR bioavailability. Tru Niagen 300 mg capsules are the most widely available standardized product.

NMN dosing. Human trials used 250 to 900 mg/day. The Yoshino 2021 Science trial used 250 mg/day and showed muscle tissue effects. A reasonable starting dose is 300 to 500 mg/day taken in the morning, since NMN may slightly activate SIRT1 pathways involved in circadian regulation.

Rapamycin dosing (longevity context). Most longevity physicians use 2 to 6 mg once weekly. Some use every-10-day or every-14-day intervals to reduce immunosuppressive burden further. Blood trough levels should remain undetectable or near the lower limit of quantification between doses when using weekly 2 to 4 mg doses.

Metformin dosing. The TAME trial uses 1 to 500 mg/day (500 mg three times daily with meals) for tolerability. Starting at 500 mg/day for two weeks before titrating up reduces gastrointestinal side effects, which affect roughly 20 to 30% of users. Extended-release formulations reduce GI complaints significantly.

NR/NMN + metformin interaction. There is a theoretical concern that metformin's AMPK activation and NR/NMN's SIRT1 activation may compete for the same NAD+ pool. This has not been confirmed in human trials, but one approach is to separate timing (NR/NMN in the morning, metformin with evening meals) to minimize any potential competition.

NR/NMN + rapamycin interaction. No known pharmacokinetic interaction. Rapamycin is a CYP3A4 substrate; NR and NMN do not meaningfully affect CYP3A4. Stacking is pharmacologically reasonable, though no RCT has tested this combination.

Who Should Not Take These Compounds Without Medical Supervision

Rapamycin absolute cautions: Active infection, planned surgery within 4 weeks, known immunodeficiency, pregnancy, current immunosuppressant use for transplant or autoimmune disease.

Metformin absolute contraindications: eGFR <30 mL/min/1.73m² (risk of lactic acidosis), active liver disease, acute or chronic metabolic acidosis, contrast dye administration within 48 hours.

NR and NMN cautions: Theoretical concern about NAD+ precursor supplementation in the context of active cancer, since tumor cells also use NAD+. This has not been confirmed as a clinical risk in human studies, but several oncologists recommend pausing NR/NMN during active cancer treatment until more data are available.

Anyone with a personal or family history of melanoma should note that NAMPT (the rate-limiting enzyme in the NAD+ salvage pathway) is upregulated in some melanomas. The clinical significance of oral NAD+ precursor supplementation in this context is unknown.